Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria

References

• Nafa K, Mason PJ, Hillmen P, et al. Mutations in the PIG-A gene causing paroxysmal nocturnal hemoglobinuria are mainly of the frameshift type. Blood. 1995;86:4650–4655.
   PubMed Web of Science ®Google Scholar
• Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124:2804–2811.
   PubMed Web of Science ®Google Scholar
• Rother RP, Bell L, Hillmen P, et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653–1662.
   PubMed Web of Science ®Google Scholar
• Peacock-Young B, Macrae FL, Newton DJ, et al. The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source. Haematologica. 2018;103:9–17.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253–1258.
   PubMed Web of Science ®Google Scholar
• Loschi M, Porcher R, Barraco F, et al. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. Am J Hematol. 2016;91:366–370.
   PubMed Web of Science ®Google Scholar
• Jang JH, Kim JS, Yoon SS, et al. Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): results from a Korean PNH Registry. J Korean Med Sci. 2016;31:214–221.
   PubMed Web of Science ®Google Scholar
• Schrezenmeier H, Maciejewski J, Roeth A, et al. Analysis of baseline clinical characteristics and disease burden in patients enrolled in the international paroxysmal nocturnal hemoglobinuria registry. Blood. 2017;130:3488.
   Web of Science ®Google Scholar
• Schrezenmeier H, Muus P, Socie G, et al. Baseline characteristics and disease burden in patients in the international paroxysmal nocturnal hemoglobinuria registry. Haematologica. 2014;99:922–929.
   PubMed Web of Science ®Google Scholar
• Schubert J, Bettelheim P, Brummendorf TH, et al. Paroxysmal nocturnal hemoglobinuria (PNH) guideline. 2012; [cited 2020 Feb 4]. Available from www.onkopedia-guidelines.info
   Google Scholar
• Patriquin CJ, Kiss T, Caplan S, et al. How we treat paroxysmal nocturnal hemoglobinuria: a consensus statement of the Canadian PNH Network and review of the national registry. Eur J Haematol. 2019;102:36–52.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Soliris (eculizumab) [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc.; 2019.
   Google Scholar
• European Medicines Agency. Soliris (eculizumab) [summary of product characteristics]. Rueil-Malmaison, France: Alexion Europe SAS; 2018.
   Google Scholar
• Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? a position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157.
   PubMed Web of Science ®Google Scholar
• Stern RM, Connell NT. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2019;10:2040620719874728.
   Web of Science ®Google Scholar
• United States Food and Drug Administration. ULTOMIRIS™ (ravulizumab-cwvz) injection [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc.; 2018.
   Google Scholar
• European Medicines Agency. Ultomiris (ravulizumab) [summary of product characteristics]. Rueil-Malmaison, France: Alexion Europe SAS; 2019.
   Google Scholar
• Alexion Pharmaceuticals Inc. ULTOMIRIS® (Ravulizumab) receives marketing authorization from japan’s ministry of health, Labour And Welfare (MHLW) for the treatment of adults with Paroxysmal Nocturnal Hemoglobinuria (PNH). Press release June 18, 2019; Available from: https://news.alexionpharma.com/press-release/product-news/ultomiris-ravulizumab-receives-marketing-authorization-japans-ministry-he
   Google Scholar
• Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233–1243.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552–559.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110:4123–4128.
   PubMed Web of Science ®Google Scholar
• Hill A, Rother RP, Wang X, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2010;149:414–425.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010;85:553–559.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Muus P, Roth A, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162:62–73.
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840–1847.
   PubMed Web of Science ®Google Scholar
• Ninomiya H, Obara N, Chiba S, et al. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2016;104:548–558.
   PubMed Web of Science ®Google Scholar
• Socie G, Caby-Tosi MP, Marantz JL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185:297–310.
   PubMed Web of Science ®Google Scholar
• Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125:775–783.
   PubMed Web of Science ®Google Scholar
• Nakayama H, Usuki K, Echizen H, et al. Eculizumab dosing intervals longer than 17 days may be associated with greater risk of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Biol Pharm Bull. 2016;39:285–288.
   PubMed Web of Science ®Google Scholar
• Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:2559–2565.
   PubMed Web of Science ®Google Scholar
• Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370:632–639.
   PubMed Web of Science ®Google Scholar
• Hill A, Rother RP, Arnold L, et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica. 2010;95:567–573.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113:4094–4100.
   PubMed Web of Science ®Google Scholar
• Subias Hidalgo M, Martin Merinero H, Lopez A, et al. Extravascular hemolysis and complement consumption in paroxysmal nocturnal hemoglobinuria patients undergoing eculizumab treatment. Immunobiology. 2017;222:363–371.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Notaro R, Pascariello C, et al. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012;119:6307–6316.
   PubMed Web of Science ®Google Scholar
• Lin Z, Schmidt CQ, Koutsogiannaki S, et al. Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. Blood. 2015;126:891–894.
   PubMed Web of Science ®Google Scholar
• Rondelli T, Risitano AM, Peffault de Latour R, et al. Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica. 2014;99:262–266.
   PubMed Web of Science ®Google Scholar
• Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. PLoS One. 2018;13:e0195909.
   PubMed Web of Science ®Google Scholar
• Roth A, Rottinghaus ST, Hill A, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Adv. 2018;2:2176–2185.
   PubMed Web of Science ®Google Scholar
• Sahelijo L, Mujeebuddin A, Mitchell D, et al. First in human single-ascending dose study: safety, biomarker, pharmacokinetics and exposure-response relationships of ALXN1210, a humanized monoclonal antibody to C5, with marked half-life extension and potential for significantly longer dosing intervals. Blood. 2015;126:4777.
   Web of Science ®Google Scholar
• Lee JW, Bachman E, Aguzzi R, et al. Immediate, complete, and sustained inhibition of C5 with ALXN1210 reduces complement-mediated hemolysis in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): interim analysis of a dose-escalation study [Abstract]. Blood. 2016;128:2428.
   Web of Science ®Google Scholar
• Peffault de Latour R, Brodsky RA, Ortiz S, et al. Ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: pharmacokinetics and pharmacodynamics observed in two phase 3 randomized, multicenter studies. Blood. 2018;132:626.
   Web of Science ®Google Scholar
• Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133:530–539.
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133:540–549.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A phase 3, open-label study of ALXN1210 in children and adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH). 2018; [cited 2020 Feb 4]. Available from https://clinicaltrials.gov/ct2/show/NCT03406507
   Google Scholar
• Schrezenmeier H, Kulasekararaj AG, Mitchell L, et al. One-year efficacy of ravulizumab (ALXN1210) in adult patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibitors [Abstract S863]. European Hematology Association, 2019; Amsterdam, The Netherlands
   Google Scholar
• Brodsky RA, Peffault de Latour R, Rottinghaus ST, et al. A prospective analysis of breakthrough hemolysis in 2 phase 3 randomized studies of Ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria [poster 2330]. Blood. 2018;132:2330.
   Google Scholar
• Peipert JD, Kulasekararaj AG, Gaya A, et al. Patient preferences for the treatment of paroxysmal nocturnal hemoglobinuria: results of a patient survey of ravulizumab (ALXN1210) and eculizumab [Poster PF734]. European Hematology Association, 2019; Amsterdam, The Netherlands
   Google Scholar
• Weitz IC, Kulagin A, Nakao S, et al. A phase 3 study of Ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria naive to complement inhibitors: results of a subgroup analysis with patients stratified by baseline hemolysis level, transfusion history, and demographics [Abstract]. Blood. 2018;132:627.
   Web of Science ®Google Scholar
• OConnell T, Buessing M, Johnson S, et al. Cost–utility analysis of ravulizumab compared with eculizumab in adult patients with paroxysmal nocturnal hemoglobinuria [Abstract PRO33]. Value Health. 2019;22:S341.
   Web of Science ®Google Scholar